

Amendments to the Specification

Please cancel all the drawings from this application.

Please amend the paragraph starting in the specification on page 53, line 4 as follows:

Compounds, which preferentially inhibit Akt/Pdk activity are shown in the table designated Group 1 compounds **figure 1**.

Please amend the paragraph starting in the specification on page 61, line 17 as follows:

Compounds, which preferentially inhibit Chk activity are shown in the table designated Group 2 compounds **figure 2**.

Please amend the paragraph starting in the specification on page 63, line 20 as follows:

Compounds, which preferentially inhibit Akt and/or Pdk and the VEGF-R activity are shown in the table designated Group 3 compounds **figure 3**.

Please amend the paragraph starting in the specification on page 64, line 3 as follows:

Further, the invention is explained in more detail by the ~~enclosed drawings and~~ examples.

Figures:







Figure Group 1 compounds: preferred compounds inhibiting preferentially Akt, Pdk kinases

Figure Group 2 compounds: preferred compounds inhibiting preferentially Chk kinases














Figure Group 3 compounds: preferred compounds inhibiting preferentially Akt and/or Pdk and VEGF-R kinases









Please insert the following onto page 64, line 11 of the application.












Group 1 compounds:







Example	structure
313	
342	 
343	 
346	






444	<div data-bbox="743 279 1125 489"> </div> <div data-bbox="1117 268 1174 289">Chiral</div> <div data-bbox="394 510 508 615"> </div>
446	<div data-bbox="711 720 1092 930"> </div> <div data-bbox="1084 709 1141 730">Chiral</div> <div data-bbox="427 835 540 940"> </div>
452	<div data-bbox="703 961 1076 1171"> </div> <div data-bbox="1068 951 1125 972">Chiral</div> <div data-bbox="443 1192 557 1297"> </div>
468	<div data-bbox="500 1360 833 1560"> </div> <div data-bbox="938 1318 1068 1423"> </div>







471	 
474	 
486	  
493	  
498	  


515	  
535	<p>Chiral</p>   
546	<p>Chiral</p>  

394	  
395	   
255	   






242	
220	
389	 
548	 

533	 <p>Chiral</p>
524	 
521	 








508	<p>Chiral</p>  <p>Three trifluoroacetic acid (TFA) molecules are shown below the structure, indicating the counterion for the chiral compound.</p> 
504	<p>Chiral</p>  <p>Three trifluoroacetic acid (TFA) molecules are shown below the structure, indicating the counterion for the chiral compound.</p> 
492	<p>Chiral</p>  <p>Two trifluoroacetic acid (TFA) molecules are shown below the structure, indicating the counterion for the chiral compound.</p> 



















Group 2 compounds:









Examples	structure
509	
516	
505	
504	
410	


490	
402	
399	
476	
450	
431	
251	
99	

A16	
A17	
A18	
103	
104	
105	
A19	

108	
109	
111	
114	
115	
108	
119	
121	









123	
124	
125	
126	
127	
129	
130	
131	









132	
133	
699	
700	
701	
702	
703	
704	













Group 3 compounds:

	structures
200	
207	
222	
230	
233	

239	
241	
242	
246	
254	
259	
261	
274	

275	
289	
297	
298	
452	
394	
395	
490	

502	
508	
509	
411	
414	
535	
539	
540	
520	

546	
547	